Histopathology News and Research

RSS

Raccoon dogs potential intermediate host for SARS-CoV-2

Researchers at the Friedrich Loeffler Institute in Germany have conducted a study demonstrating that raccoon dogs were a potential intermediate host in the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

23 Aug 2020

Researchers develop 3D imaging technique to visualize damaged lung tissue after severe COVID-19

Physicists at the University of Göttingen, together with pathologists and lung specialists at the Medical University of Hannover, have developed a three-dimensional imaging technique that enables high resolution and three-dimensional representation of damaged lung tissue following severe Covid-19.

21 Aug 2020

New SARS-CoV-2 vaccine effective in macaques

Researchers from the biotechnology company Novavax in Gaithersburg, Maryland, have developed a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that successfully induces immunogenicity and protection against the virus in macaques.

20 Aug 2020

COVID-19 during pregnancy shows no affect on placental structure and pathology

A new study published on the preprint server medRxiv in August 2020 shows that the placenta in pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) does not show any signs of abnormality that can be attributed to the infection.

14 Aug 2020

An 'intelligent' strategy for real-time evaluation of photothermal therapy efficiency on tumors

Photothermal therapy (PTT) is a promising alternative method for cancer treatment due to advantages of non-invasiveness, precise temporal and spatial control, strong specificity and high tumor destruction efficiency.

6 Aug 2020

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

Researchers in the U.S. have shown both preventive and treatment effects of an antibody cocktail in animal models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2020

Gene signature explains why 18F-FDG imaging performs better for PSMA-suppressed prostate cancer patients

Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA).

23 Jul 2020

Ultivue and OracleBio partner to help advance personalized tumor characterization and clinical oncology research using multiplex immunofluorescence

Ultivue and OracleBio partner to help further insights and advance personalized tumor characterization in translational and clinical oncology research.

From Ultivue 23 Jul 2020

Silver-plated gold nanostars could be used to identify early biomarkers of cancer

Biomedical engineers at Duke University have engineered a method for simultaneously detecting the presence of multiple specific microRNAs in RNA extracted from tissue samples without the need for labeling or target amplification.

21 Jul 2020

Evidence of SARS-CoV-2 placental infection in mild COVID-19

Now, a new study published on the preprint server medRxiv* in July 2020 reveals evidence of placental infection and hypoxia, despite the lack of serious symptoms in the mother.

16 Jul 2020

Researchers develop bioprinted skin model of cutaneous squamous cell carcinoma

The cover for issue 27 of Oncotarget features "Bimodal imaging examples of control and treated tumors (red) before and after the treatment period," by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.

7 Jul 2020

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

New polymeric heart valve is a promising alternative for valve replacement surgery, study shows

A new polymeric heart valve with a life span potentially longer than current artificial valves that would also prevent the need for the millions of patients with diseased heart valves to require life-long blood thinning tablets has been developed by scientists at the universities of Bristol and Cambridge.

29 Jun 2020

Chilblains and COVID-19

The current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily a respiratory infection, though the majority of cases are asymptomatic or mild disease. However, other manifestations are also being reported, such as gastrointestinal features, neurological signs, and skin symptoms. A new study published online in the journal JAMA Dermatology in June 2020 examines the possibility that chilblains could be a manifestation of COVID-19.

26 Jun 2020

St. Jude scientists create O-PDX models for pediatric brain tumor research

Scientists at St. Jude Children's Research Hospital have created orthotopic patient-derived xenograft (O-PDX) models representing a variety of pediatric brain tumor types.

23 Jun 2020

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Accelerating the Diagnosis and Treatment of Cancer with Mass-Spectrometry Based Techniques

An interview with Livia Eberlin, Assistant Professor at the University of Texas at Austin, discussing the development of mass-spectrometry based techniques for cancer diagnosis and improved clinical outcomes.

From Pittcon 16 Jun 2020

Hydroxychloroquine ineffective in animal SARS-CoV-2 infection

A new study by scientists from the U.S and U.K. and published on the preprint server bioRxiv in June 2020 reports that there is no evidence of efficacy for the drug hydroxychloroquine (HCQ) against infection with SARS-CoV-2 in hamsters or macaque models. This finding does not support the current widespread prophylactic and therapeutic use of HCQ in COVID-19.

14 Jun 2020

Pre-clinical data for Celltrion’s antiviral antibody treatment shows 100-fold reduction in viral load of SARS-CoV-2

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.

4 Jun 2020

IL-6 blocker use in severe COVID-19 increases risk of secondary infections

With many hundreds of thousands of deaths due to the current COVID-19 pandemic, there is a rush to find an effective vaccine or drug against the virus. A new study on the preprint server medRxiv* in May 2020 shows that the use of some biologically plausible drugs may be counterproductive, and care should be taken when trying out unproven therapies.

22 May 2020